Topical cyclosporine in pediatric keratoplasty

Eye Contact Lens. 2003 Apr;29(2):103-7. doi: 10.1097/01.ICL.0000062460.03555.32.


Purpose: To evaluate the efficacy and safety of combined treatment with 2% topical cyclosporine (CsA) and topical corticosteroid compared to treatment with topical corticosteroids only after pediatric keratoplasty.

Methods: Twenty-two grafts in 16 pediatric patients were evaluated retrospectively. The eyes were divided into a CsA group (9 eyes) and a control group (13 eyes) based on the postoperative treatment regimen. Information reviewed included patient age and sex, clinical diagnosis; preoperative and postoperative intraocular pressure and lens status; previous, concurrent, and subsequent surgical procedures; operative and postoperative complications; number of graft rejections, timing of suture removal, and length of follow-up. The clinical outcome of penetrating keratoplasty (PK) was evaluated by the rate of rejection-free graft survival and graft survival evaluation by the Kaplan-Meier log-rank test.

Results: The rejection-free graft survival rate was 88.9% in the CsA group and 38.5% in the control group. This difference in rejection-free graft survival rate between the groups was statistically significant (P =.0465). The graft survival rate was 88.9% in the CsA group and 46.2% in the control group. The difference in the graft survival rate was not statistically significant between the groups (P =.6). No clinical signs of systemic or local toxicity were seen with the topical CsA treatment.

Conclusions: Two percent topical CsA is safe and effective in reducing the risk of allograft rejection in pediatric recipients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Anti-Inflammatory Agents / administration & dosage
  • Child
  • Child, Preschool
  • Cornea / drug effects*
  • Cyclosporine / administration & dosage*
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids
  • Graft Rejection / prevention & control*
  • Graft Survival / drug effects
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Infant
  • Intraocular Pressure
  • Keratoplasty, Penetrating*
  • Male
  • Retrospective Studies
  • Safety
  • Visual Acuity


  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Immunosuppressive Agents
  • Cyclosporine